A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 6, 2014

99% Cure Rates for AbbVie’s Hep C Combo in Genotype 1b

CROI 2014AbbVie’s investigational triple-combination therapy cured close to 100 percent of people with genotype 1b of hepatitis C virus (HCV) in a large Phase III trial, MedPage Today reports. K. Rajender Reddy, MD, of the University of Pennsylvania presented findings from the PEARL-III trial at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The results position AbbVie in a competitive position against Gilead Sciences’ combination pill of Sovaldi (sofosbuvir) and its investigational drug ledipasvir, which has had similarly stellar results in clinical trials. Gilead filed for approval for that combination therapy on February 19. Some have theorized that AbbVie may attempt to undercut Gilead on price, leading insurers to overlook the raised pill burden of AbbVie’s option if it works as well as Gilead’s therapy.

The AbbVie trial included 419 participants who received 12 weeks, with or without ribavirin, of the so-called “three-D” therapy: the ritonavir-boosted protease inhibitor ABT-450/r (a coformulated pill of the two drugs), the NS5A inhibitor ABT-267 and the non-nucleoside NS5B inhibitor ABT-333.

A total of 99.5 percent of those who took ribavirin and 99 percent of those who did not achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). The researchers concluded that ribavirin offered no treatment advantage.

Of the just three people who did not achieve an SVR12, two were lost to follow-up and one developed a resistance mutation during treatment and experienced virologic failure.

The major adverse side effects were headache, fatigue, itching, nausea and weakness. The rates of the latter two side effects were significantly greater among those taking ribavirin.

To read the MedPage Today story, click here.

Search: AbbVie, three-D, K. Rajender Reddy, University of Pennsylvania, Conference on Retroviruses and Opportunistic Infections, Gilead Sciences, Sovaldi, sofosbuvir, ledipasvir, ritonavir, ABT-450/r, ABR-267, ABT-333.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dversescott
    Baltimore
    Maryland


    zeze42
    Bay Area - Peninsula
    California


    youngbloodlatino
    Columbia
    Maryland


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.